Risevistinel

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameRisevistinel
Drug Alias NameNYX-783
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor modulatorsprotein allosteric modulators
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsStress Disorders, Post-TraumaticOpioid-Related Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAptinyx Inc
China Registration ClassN/A

Develop Information

Active CompaniesYale University
Inactive CompaniesAptinyx Inc
Active IndicationsOpioid-Related Disorders
Inactive IndicationsStress Disorders, Post-Traumatic

Other Information

ATC CodeN/A
Related LinksN/A